Abeona Therapeutics to Present at the 10th Annual SVB Leerink Global Healthcare Conference
February 22 2021 - 7:30AM
Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader
in gene and cell therapy, today announced that the company will
present at the 10th Annual SVB Leerink Global Healthcare Conference
on Wednesday, February 24, 2021 at 11:20 am EST.
A live webcast of the presentation will be
available on the investor section of the Abeona Therapeutics
website, www.abeonatherapeutics.com, and an archived replay will be
accessible for up to 30 days.
About Abeona Therapeutics
Abeona Therapeutics Inc. is a clinical-stage
biopharmaceutical company developing gene and cell therapies for
serious diseases. Abeona’s clinical programs include EB-101, its
autologous, gene-corrected cell therapy for recessive dystrophic
epidermolysis bullosa in Phase 3 development, as well as ABO-102
and ABO-101, novel AAV-based gene therapies for Sanfilippo syndrome
types A and B (MPS IIIA and MPS IIIB), respectively, in Phase 1/2
development. The Company’s portfolio also features AAV-based gene
therapies for ophthalmic diseases with high unmet medical needs.
Abeona’s novel, next-generation AIM™ capsids have shown potential
to improve tropism profiles for a variety of devastating diseases.
Abeona’s fully functional, gene and cell therapy GMP manufacturing
facility produces EB-101 for the pivotal Phase 3 VIITAL™ study and
is capable of clinical and commercial production of AAV-based gene
therapies. For more information, visit
www.abeonatherapeutics.com.
Forward-Looking Statements
This press release contains certain statements
that are forward-looking within the meaning of Section 27A of the
Securities Act of 1933, as amended, and Section 21E of the
Securities Exchange Act of 1934, as amended, and that involve risks
and uncertainties. These statements include statements about the
Company exploring all strategic options, including the sale of some
or all of its assets or sale of the Company. We have attempted to
identify forward-looking statements by such terminology as “may,”
“will,” “believe,” “estimate,” “expect,” and similar expressions
(as well as other words or expressions referencing future events,
conditions or circumstances), which constitute and are intended to
identify forward-looking statements. Actual results may differ
materially from those indicated by such forward-looking statements
as a result of various important factors, numerous risks and
uncertainties, including but not limited to the potential impacts
of the COVID-19 pandemic on our business, operations, and financial
condition, the outcome of the strategic review, continued interest
in our rare disease portfolio, our ability to enroll patients in
clinical trials, the outcome of any future meetings with the U.S.
Food and Drug Administration or other regulatory agencies, the
impact of competition, the ability to secure licenses for any
technology that may be necessary to commercialize our products, the
ability to achieve or obtain necessary regulatory approvals, the
impact of changes in the financial markets and global economic
conditions, risks associated with data analysis and reporting, and
other risks disclosed in the Company’s most recent Annual Report on
Form 10-K and subsequent quarterly reports on Form 10-Q and other
periodic reports filed with the Securities and Exchange Commission.
The Company undertakes no obligation to revise the forward-looking
statements or to update them to reflect events or circumstances
occurring after the date of this press release, whether as a result
of new information, future developments or otherwise, except as
required by the federal securities laws.
Investor and Media Contact:
Greg Gin
VP, Investor Relations and Corporate Communications
Abeona Therapeutics
+1 (646) 813-4709
ggin@abeonatherapeutics.com
Abeona Therapeutics (NASDAQ:ABEO)
Historical Stock Chart
From Mar 2024 to Apr 2024
Abeona Therapeutics (NASDAQ:ABEO)
Historical Stock Chart
From Apr 2023 to Apr 2024